AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name…
BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment engine breaking the bottleneck in…
Accomplished biotech and CRO leader brings 25+ years of global oncology drug development and operational excellence to propel Emerald's continued…
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
SRM University-AP, Amaravati, is inviting applications from exceptional athletes and champions for admission under the sports quota for the academic…
October 24, 2025 07:02 ET | Source: Kura Oncology, Inc. - Milestone triggered by dosing of first patient in frontline…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…